Literature DB >> 1706606

SIV, STLV-I and type D retrovirus antibodies in captive rhesus macaques and immunoblot reactivity to SIV p27 in human and rhesus monkey sera.

M D Lairmore1, N W Lerche, K T Schultz, C M Stone, B G Brown, L M Hermann, J A Yee, M Jennings.   

Abstract

The prevalence of simian immunodeficiency virus (SIV), simian T-cell lymphotropic virus type 1 (STLV-I), and type D retrovirus (SRV-D) antibodies was determined for 1229 rhesus monkeys (Macaca mulatta) from two research colonies. Serum samples were tested by using enzyme-linked immunosorbent assay (ELISA), immunoblot (IB), and radioimmunoprecipitation assay (RIPA). Seropositive results for the three retroviruses tested were 0 for SIV, 270 (22%) for STLV-I, and 103 (8.4%) for type D retrovirus. Of the rhesus monkey sera, 61 (5.0%) were reactive to SIV gag p27 only, when tested by IB, but were negative when further tested by RIPA. Virus isolation was attempted from cultured peripheral blood mononuclear cells of 35 monkeys whose sera contained only p27 reactivity and none were positive by reverse transcriptase and core antigen assays to detect SIV. No overt clinical signs of immunodeficiency disease or unexplained deaths were evident in either monkey colony. Additionally, 63 of 165 (38%) human sera from various groups (primate center workers, normal donors, health care workers) had weak to moderate IB reactivity only to SIV p27, but 31 of 31 sera tested were negative by RIPA. These sera remained reactive to SIV p27 following absorption with an uninfected cell lysate, after blocking IB strips with various blocking solutions and were reactive to different SIV antigen preparations while remaining negative to human immunodeficiency virus type 1 (HIV-1) by IB and negative to HIV-2 by ELISA. These data underscore the need to adopt criteria for a positive SIV serologic test requiring reactivity against more than one viral gene product. These results also illustrate a potential problem in the testing of human sera for antibodies against simian retroviruses and demonstrate the need for caution in the interpretation of immunoblot results.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1706606     DOI: 10.1089/aid.1990.6.1233

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  5 in total

1.  Simultaneous detection of antibodies to five simian viruses in nonhuman primates using recombinant viral protein based multiplex microbead immunoassays.

Authors:  Qi Liao; Huishan Guo; Min Tang; Neal Touzjian; Nicholas W Lerche; Yichen Lu; JoAnn L Yee
Journal:  J Virol Methods       Date:  2011-09-17       Impact factor: 2.014

2.  Serologic confirmation of simian T-lymphotropic virus type I infection by using immunoassays developed for human T-lymphotropic virus antibody detection.

Authors:  D L Rudolph; J Yee; J Mone; S K Foung; J J Lipka; G R Reyes; K Hadlock; L Chan; F Villinger; M D Lairmore
Journal:  J Clin Microbiol       Date:  1992-04       Impact factor: 5.948

Review 3.  Specific pathogen free macaque colonies: a review of principles and recent advances for viral testing and colony management.

Authors:  JoAnn L Yee; Thomas H Vanderford; Elizabeth S Didier; Stanton Gray; Anne Lewis; Jeffrey Roberts; Kerry Taylor; Rudolf P Bohm
Journal:  J Med Primatol       Date:  2016-03-01       Impact factor: 0.667

4.  Immune recognition of genetically diverse simian T-cell lymphotropic virus type I isolates.

Authors:  A Lazo; R T Bailer; J R Blakeslee; R Yanagihara; V C Stevens; L Kramer; M D Lairmore
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

5.  Characterization of simian T-cell leukemia virus type 1 in naturally infected Japanese macaques as a model of HTLV-1 infection.

Authors:  Michi Miura; Jun-ichiro Yasunaga; Junko Tanabe; Kenji Sugata; Tiejun Zhao; Guangyong Ma; Paola Miyazato; Koichi Ohshima; Akihisa Kaneko; Akino Watanabe; Akatsuki Saito; Hirofumi Akari; Masao Matsuoka
Journal:  Retrovirology       Date:  2013-10-24       Impact factor: 4.602

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.